ABCSG 46/CompLEEment-1 Summary
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.
|Coordinating Investigator:||Bartsch, Rupert; Wien|
|Sample size:||3.000 (international), 30 (national)|
(Click to open)